Clinical Trial

Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated September 17, 2025 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The objective of the proposed work is to determine whether administration for 12 months of romosozumab followed by 12 months of denosumab will maintain bone mass at the knee in subjects with subacute SCI compared to 24 months of denosumab administration alone.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-10-28; most recent amendment 2025-09-11.
Status change: Recruiting → Active, Not Recruiting 2024-02-29
Trial Details
NCT Number NCT05101018
Lead Sponsor James J. Peters Veterans Affairs Medical Center
Collaborators: Kessler Institute for Rehabilitation
Conditions Osteoporosis, Spinal Cord Injuries
Enrollment 40 participants
Start Date 2021-11-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2027-11-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-17